<DOC>
	<DOC>NCT02452307</DOC>
	<brief_summary>The study evaluates the prostate-specific antigen (PSA) response in HLA-A*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine in combination with different immune-adjuvants.</brief_summary>
	<brief_title>Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy</brief_title>
	<detailed_description>Patients with a biochemical recurrence after initial therapy can be included.</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Freund's Adjuvant</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>biochemical recurrence after Radical Prostatectomy no clinical metastases in CT or bone scan HLAType: HLAA*02 positive KarnofskyPerformanceIndex &gt;70 Age &gt;45 / &lt;80 years no prior or ongoing hormonal therapy no ongoing radiation therapy SerumCreatinine &lt;2mg/dl; Bilirubin: &lt;2gm/dl no history of allergy or chronic obstructive lung disease (COLD) Patients unable to consent KarnofskyPerformanceIndex &lt;70 known allergy or COLD presence of secondary malignancy prior or ongoing hormonal treatment ongoing radiotherapy immunosuppressive medication seizure</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>